Novo Nordisk continues to stack obesity pipeline, this time with Swiss zebrafish biotech

No­vo Nordisk li­censed an ex­per­i­men­tal obe­si­ty pill from Er­a­Cal Ther­a­peu­tics in a deal worth €235 mil­lion, or rough­ly $255 mil­lion, as it hunts for the next gen­er­a­tion of weight man­age­ment med­i­cines.

Un­like No­vo’s wide­ly-known weight loss in­jec­tion We­govy, the Er­a­Cal pro­gram is an oral small mol­e­cule. It “is be­lieved to tar­get a nov­el mech­a­nism of ac­tion con­trol­ling ap­petite and body weight to treat obe­si­ty,” Er­a­Cal said in a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.